Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell the weight loss drug Wegovy on its platform [3]. Group 3: Allegations and Impact - Hims & Hers allegedly misrepresented the nature of its partnership with Novo Nordisk, claiming it could offer both Wegovy and compounded semaglutide, and that its sales complied with FDA regulations [4]. - Following Novo Nordisk's announcement on June 23, 2025, that it was terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24, or over 34%, from $64.22 to $41.98 per share [5].

Company Overview - Hims & Hers transformed from a startup to a telehealth company valued at nearly $11 billion [1] Business Model - The company became a leader in knockoff weight-loss drugs [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of misleading statements and unsafe practices related to the promotion of drugs, particularly in connection with a terminated partnership with Novo Nordisk [2][4][5]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Hims to contact them for discussing legal options [1]. - The firm is investigating claims against Hims and reminds investors of the August 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action [2]. - The complaint alleges that Hims engaged in deceptive promotion and selling of illegitimate drugs, risking patient safety and misleading investors about the company's operations and prospects [4]. Group 2: Partnership Termination and Stock Impact - Novo Nordisk announced the termination of its partnership with Hims, citing violations of laws regarding the sale of compounded drugs and deceptive marketing practices [5]. - Following the announcement, Hims' stock price fell by $22.24, or 34.6%, closing at $41.98 per share, significantly impacting investors [5]. Group 3: Class Action and Lead Plaintiff Information - The court-appointed lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [6]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [6]. Group 4: Whistleblower Encouragement - Faruqi & Faruqi, LLP is encouraging individuals with information regarding Hims' conduct, including whistleblowers and former employees, to contact the firm [7].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between April 29, 2025, and June 23, 2025 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Hims engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, which jeopardized patient safety [2] - It is alleged that this situation posed a significant risk of termination of the Company's collaboration with Novo Nordisk [2] - The defendants' positive statements regarding the Company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell the weight loss drug Wegovy on its platform [3]. Group 3: Allegations of Misrepresentation - Hims & Hers allegedly misrepresented the nature of its partnership with Novo Nordisk, claiming it could offer both Wegovy and compounded semaglutide, and that its sales complied with FDA regulations [4]. Group 4: Stock Market Reaction - Following Novo Nordisk's announcement on June 23, 2025, that it was terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24, or over 34%, from $64.22 to $41.98 per share [5].

SAN DIEGO, July 14, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, both dates inclusive (the "Class Period"), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers as well as ...

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell the weight loss drug Wegovy on its platform [3]. Group 3: Allegations of Misrepresentation - Hims & Hers allegedly misrepresented the nature of its partnership with Novo Nordisk, claiming it could offer both Wegovy and compounded semaglutide to customers [4]. - The company also purportedly stated that its sale of compounded semaglutide complied with FDA regulations [4]. Group 4: Stock Market Reaction - Following Novo Nordisk's announcement on June 23, 2025, that it was terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24 per share, a decline of over 34%, from $64.22 to $41.98 [5].

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. - Two complaints have been filed, with the first case titled Sookdeo v. Hims & Hers Health, Inc., and a subsequent similar complaint titled Yaghsizian v. Hims & Hers Health, Inc. [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy, which contains the active ingredient semaglutide [3]. - Allegations state that Hims & Hers misrepresented the nature of its partnership with Novo Nordisk and claimed compliance with FDA regulations regarding the sale of compounded semaglutide [4]. Group 3: Stock Impact - Following the announcement of the termination of the partnership by Novo Nordisk due to Hims & Hers' alleged deceptive practices, the stock price fell by $22.24, a decline of over 34%, from $64.22 to $41.98 per share [5].

Core Viewpoint - Hims & Hers Health, Inc. is facing two securities class action lawsuits due to allegations of deceptive marketing practices and failure to disclose critical information, particularly related to its collaboration with Novo Nordisk and the weight loss drug Wegovy® [1][4][5] Group 1: Lawsuits and Allegations - Two class action lawsuits were filed against Hims & Hers Health, Inc. and certain executives, representing investors who acquired securities between April 29, 2025, and June 23, 2025 [1] - The lawsuits allege that Hims & Hers made false and misleading statements and engaged in deceptive promotion of knockoff versions of Wegovy®, which jeopardized patient safety and led to the termination of its collaboration with Novo Nordisk [4][5] - The lawsuits were prompted by Novo Nordisk's announcement on June 23, 2025, that it terminated its collaboration due to concerns over Hims & Hers' illegal practices and deceptive marketing [2][5] Group 2: Investor Impact and Actions - Following the termination of the collaboration, Hims & Hers shares experienced a significant decline of 30% [2] - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to submit their losses [3][6] - The lead plaintiff deadline for the lawsuits is set for August 25, 2025 [3] Group 3: Whistleblower Information - Individuals with non-public information regarding Hims & Hers are encouraged to assist in the investigation or consider the SEC Whistleblower program, which offers rewards for original information leading to successful recoveries [7]

Hims & Hers Health shares rose after the telehealth company announced plans to expand into Canada next year, timed with the anticipated availability of generic semaglutide. https://t.co/Tf5Ox3DVpj ...